During shared decision-making about an antihypertensive medication, which patient-oriented outcome is most important to discuss?

During shared decision-making about an antihypertensive medication, which patient-oriented outcome is most important to discuss?

• A. A reduction in blood pressure
• B. No change in outcomes
• C. Only cost considerations
• D. A decrease in all-cause mortality

Answer: (D)

Shared decision-making about antihypertensive therapy should center on outcomes that truly matter to patients. While lowering blood pressure is useful, it’s a surrogate measure; what patients care about most is how the treatment affects their survival and overall well-being. A decrease in all-cause mortality directly speaks to longevity and ultimate health benefit, making it the most meaningful patient-oriented outcome to discuss. It translates the treatment’s effect into something tangible about living longer, which patients can weigh against potential side effects, daily impact, and personal preferences. Cost and other factors matter for feasibility, but they don’t carry the same weight as whether a medication can shorten the risk of death. If possible, translate the benefit into absolute risk reduction or numbers needed to treat to help the patient grasp the real-world impact.

Shared decision-making about antihypertensive therapy should center on outcomes that truly matter to patients. While lowering blood pressure is useful, it’s a surrogate measure; what patients care about most is how the treatment affects their survival and overall well-being. A decrease in all-cause mortality directly speaks to longevity and ultimate health benefit, making it the most meaningful patient-oriented outcome to discuss. It translates the treatment’s effect into something tangible about living longer, which patients can weigh against potential side effects, daily impact, and personal preferences. Cost and other factors matter for feasibility, but they don’t carry the same weight as whether a medication can shorten the risk of death. If possible, translate the benefit into absolute risk reduction or numbers needed to treat to help the patient grasp the real-world impact.